Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner
- 14 July 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (2), 368-379
- https://doi.org/10.1182/blood-2010-12-326058
Abstract
Both monoallelic and biallelic oncogenic NRAS mutations are identified in human leukemias, suggesting a dose-dependent role of oncogenic NRAS in leukemogenesis. Here, we use a hypomorphic oncogenic Nras allele and a normal oncogenic Nras allele (Nras G12Dhypo and Nras G12D, respectively) to create a gene dose gradient ranging from 25% to 200% of endogenous Nras G12D/+. Mice expressing Nras G12Dhypo/G12Dhypo develop normally and are tumor-free, whereas early embryonic expression of Nras G12D/+ is lethal. Somatic expression of Nras G12D/G12D but not Nras G12D/+ leads to hyperactivation of ERK, excessive proliferation of myeloid progenitors, and consequently an acute myeloproliferative disease. Using a bone marrow transplant model, we previously showed that ∼ 95% of animals receiving Nras G12D/+ bone marrow cells develop chronic myelomonocytic leukemia (CMML), while ∼ 8% of recipients develop acute T-cell lymphoblastic leukemia/lymphoma [TALL] (TALL-het). Here we demonstrate that 100% of recipients transplanted with Nras G12D/G12D bone marrow cells develop TALL (TALL-homo). Although both TALL-het and -homo tumors acquire Notch1 mutations and are sensitive to a γ-secretase inhibitor, endogenous Nras G12D/+ signaling promotes TALL through distinct genetic mechanism(s) from Nras G12D/G12D. Our data indicate that the tumor transformation potential of endogenous oncogenic Nras is both dose- and cell type-dependent.Keywords
This publication has 52 references indexed in Scilit:
- A restricted spectrum of NRAS mutations causes Noonan syndromeNature Genetics, 2009
- 250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid MalignanciesCancer Research, 2008
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic CorrelatesCancer Cell, 2008
- Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formationNature, 2008
- K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsBlood, 2006
- Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in miceBlood, 2006
- Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry–based novel culture systemBlood, 2003
- Inducible Gene Targeting in MiceScience, 1995
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994
- The GTPase superfamily: conserved structure and molecular mechanismNature, 1991